thalidomide has been researched along with Mastocytosis, Systemic in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Mastocytosis, Systemic: A group of disorders caused by the abnormal proliferation of MAST CELLS in a variety of extracutaneous tissues including bone marrow, liver, spleen, lymph nodes, and gastrointestinal tract. Systemic mastocytosis is commonly seen in adults. These diseases are categorized on the basis of clinical features, pathologic findings, and prognosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "Thalidomide seems to be an active drug in advanced SM." | 1.35 | Thalidomide in advanced mastocytosis. ( Bernit, E; Canioni, D; Claisse, JF; Damaj, G; Ghez, D; Harlé, JR; Hermine, O; Schleinitz, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 2 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 2 |
| Damaj, G | 2 |
| Kluin-Nelemans, HC | 1 |
| Ferenc, V | 1 |
| van Doormaal, JJ | 1 |
| van Iperen, C | 1 |
| Peters, WG | 1 |
| Akin, C | 1 |
| Valent, P | 1 |
| Bernit, E | 1 |
| Ghez, D | 1 |
| Claisse, JF | 1 |
| Schleinitz, N | 1 |
| Harlé, JR | 1 |
1 trial available for thalidomide and Mastocytosis, Systemic
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
2 other studies available for thalidomide and Mastocytosis, Systemic
| Article | Year |
|---|---|
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple | 2009 |
Thalidomide in advanced mastocytosis.
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow Cells; Female; Follow-Up Studies; Humans; Immunosuppressi | 2008 |